Bridgeway Capital Management, LLC In8 Bio, Inc. Transaction History

Bridgeway Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.95 - $1.69 $23,750 - $42,250	25,000 Added 31.93%	103,302 $121,000
Q3 2023 Nov 14, 2023	BUY	$0.92 - $1.74 $26,957 - $50,985	29,302 Added 59.8%	78,302 $81,000
Q2 2023 Aug 14, 2023	SELL	$1.05 - $3.24 $26,250 - $81,000	-25,000 Reduced 33.78%	49,000 $75,000
Q3 2022 Nov 14, 2022	BUY	$1.77 - $2.89 $24,780 - $40,460	14,000 Added 23.33%	74,000 $149,000
Q1 2022 May 16, 2022	BUY	$2.76 - $4.6 $165,600 - $276,000	60,000 New	60,000 $208,000

7.62M

Ticker INAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,502,200
Market Cap $6.13M
Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.